ClinicalTrials.gg
RecruitingNCT07063342Updated Aug 17, 2026

A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses

A Phase 1 interventional study of Xanomeline/Trospium Chloride Capsule and Xanomeline Enteric Capsule in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, to explore the effect of food after multiple doses of selected prototypes, and to evaluate alternative formulations of KarX and KarXT following single and multiple ascending doses in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • between 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Part 1

    Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule · Drug: Trospium Chloride

  • Experimental
    Part 2

    Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule · Drug: Xanomeline MR

  • Experimental
    Part 3a

    Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule

  • Experimental
    Part 3b

    Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule · Drug: Xanomeline MR

  • Experimental
    Part 4a

    Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline · Drug: Placebo

  • Experimental
    Part 4b

    Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline · Drug: Placebo

Interventions

  • DrugXanomeline/Trospium Chloride Capsule

    Drug pages: Xanomeline · Trospium chloride

    Specified dose on specified days

    Also known as: BMS-986510, KarXT

  • Specified dose on specified days

    Also known as: BMS-986519, KarX-EC

  • Specified dose on specified days

    Also known as: BMS-986520, KarT

  • Specified dose on specified days

    Also known as: BMS-986519, KarX-MR

  • Specified dose on specified days

    Also known as: BMS-986519, KarX

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to Day 23

  2. Time of maximum observed concentration (Tmax)

    Time frame: Up to Day 23

  3. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 23

  4. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to Day 23

  5. Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Time frame: Up to Day 23

  6. Concentration at the end of a dosing interval (Ctau)

    Time frame: Up to Day 23

  7. Apparent total body clearance (CLT/F)

    Time frame: Up to Day 23

  8. Effective elimination half-life during dosing interval (T-HALF(eff))

    Time frame: Up to Day 23

  9. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 30 days after final dose of study intervention

  10. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to 30 days after final dose of study intervention

  11. Number of participants with Adverse Events of Special Interest (AESIs)

    Time frame: Up to 30 days after final dose of study intervention

  12. Number of participants with AEs leading to discontinuation

    Time frame: Up to 30 days after final dose of study intervention

  13. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Day 14

Secondary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 30 days after final dose of study intervention

  2. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to 30 days after final dose of study intervention

  3. Number of participants with Adverse Events of Special Interest (AESIs)

    Time frame: Up to 30 days after final dose of study intervention

  4. Number of participants with AEs leading to discontinuation

    Time frame: Up to 30 days after final dose of study intervention

  5. Number of participants with vital signs abnormalities

    Time frame: Up to 30 days after final dose of study intervention

  6. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 30 days after final dose of study intervention

  7. Number of participants with physical examination abnormalities

    Time frame: Up to 30 days after final dose of study intervention

  8. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 30 days after final dose of study intervention

  9. Geometric mean ratio of Cmax

    Time frame: Up to Day 12

  10. Geometric mean ratio of AUC(0-T)

    Time frame: Up to Day 12

  11. Geometric mean ratio of AUC(INF)

    Time frame: Up to Day 12

  12. Geometric mean ratio of area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Time frame: Up to Day 12

  13. Maximum observed concentration (Cmax)

    Time frame: Up to Day 16

  14. Time of maximum observed concentration (Tmax)

    Time frame: Up to Day 16

  15. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 16

  16. Area under the plasma concentration-time curve from time zero to 12 hours (AUC(0-12))

    Time frame: Up to Day 4

  17. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to Day 23

  18. Apparent total body clearance (CLT/F)

    Time frame: Up to Day 16

  19. Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Time frame: Up to Day 16

  20. Effective elimination half-life during dosing interval (T-HALF(eff))

    Time frame: Up to Day 16

  21. Cmax Accumulation Index: Ratio of Cmax at steady state to Cmax after first dose (AI_Cmax)

    Time frame: Up to Day 16

  22. AUC(TAU) Accumulation Index: Ratio of AUC(TAU) at steady state to AUC(TAU) after first dose (AI_AUC)

    Time frame: Up to Day 16

07

Study locations

1 of 1 sites recruiting
  • Quotient Sciences
    Nottingham, Nottinghamshire NG1 6JS, United Kingdom
    Recruiting
    • Philip Evans, Site 0001 · Contact4401159749000
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 14, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Mar 29, 2027
CompletionEst.
Mar 29, 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07063342
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jun 27, 2025
Primary completion
Mar 29, 2027 (estimated)
Completion
Mar 29, 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion